Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
Pituitary adenomas in childhood and adolescence constitute 2-6% of all operated pituitary adenomas. We report the clinical features, treatment and follow-up of 10 pediatric patients affected by pituitary adenomas. All patients underwent clinical evaluation, endocrine tests, magnetic resonance imaging and visual field assessment. Follow-up ranged from 8 to 132 months (median 52.6). All patients were older than 10 years of age; 60% were males. In 50% the initial complaints were headache and/or visual impairment, all except one had clear evidence of endocrine dysfunction. Ninety percent were macroadenomas. According to hormone measurements and immunostaining 50% were prolactinomas, 20% were pure GH-secreting and 30% were non-functioning adenomas. Prolactinomas in two females were successfully treated with cabergoline. The other patients underwent surgery: three prolactinomas are still being treated with dopamine agonists and a GH-secreting adenoma is being treated with octreotide LAR and cabergoline. Two patients were also treated with conventional radiotherapy. Treatments were completely successful in 50% of patients: these have normal hormone secretion, full pubertal development, no significant tumor mass and normal visual field. Hypersecretion of prolactin persists in two cases; partial or complete hypopituitarism is present in four, relevant tumor remnant in another four and impairment of visual field is present in two cases. In conclusion, pediatric adenomas occur mostly in pubertal age, are prevalently macroadenomas and clinically functioning. Medical therapy should be preferred for secreting adenomas, but in some cases, notably prolactinomas in males, surgery and eventual radiotherapy may be needed.
De Menis
E
E
I Medical Division, Regional Hospital, Treviso, Italy. edemenis@ulss.tv.it
Visentin
A
A
Billeci
D
D
Tramontin
P
P
Agostini
S
S
Marton
E
E
Conte
N
N
D000172:Acromegaly; D000236:Adenoma / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy; D000293:Adolescent; D000568:Amenorrhea; D001971:Bromocriptine / Q000627:therapeutic use; D000077465:Cabergoline; D002648:Child; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D006261:Headache; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D015282:Octreotide / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy; D015175:Prolactinoma / Q000175:diagnosis / Q000601:surgery / Q000628:therapy; D011628:Puberty, Delayed; D011878:Radiotherapy; D016896:Treatment Outcome; D014786:Vision Disorders; D014794:Visual Fields
D004873:Ergolines; D019382:Human Growth Hormone; D001971:Bromocriptine; D000077465:Cabergoline; D015282:Octreotide